(289) Peptide-Guided Nanoparticles for Targeted Temozolomide Delivery in Glioblastoma

Introduction: Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor, with limited treatment options and a poor 5-year survival rate of only 5%. Chemotherapy with temozolomide is limited by the systemic toxicity and occurred resistance of the drug. Temozolomide (TMZ) based nanomedicine, in combination with precision and high affinity targeting with GBM-homing peptides, represents a promising strategy for selective GBM therapy in xenograft murine model of GBM.